Altimmune Inc
ALT
Company Profile
Business description
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Contact
910 Clopper Road
Suite 201S
GaithersburgMD20878
USAT: +1 240 654-1450
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
59
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,213.20 | 38.10 | 0.47% |
| CAC 40 | 7,536.26 | 33.48 | 0.45% |
| DAX 40 | 22,242.45 | 177.94 | 0.81% |
| Dow JONES (US) | 40,113.50 | 20.10 | 0.05% |
| FTSE 100 | 8,415.25 | 7.81 | 0.09% |
| HKSE | 22,041.20 | 60.46 | 0.28% |
| NASDAQ | 17,382.94 | 216.90 | 1.26% |
| Nikkei 225 | 35,837.15 | 131.41 | 0.37% |
| NZX 50 Index | 12,098.89 | 81.05 | 0.67% |
| S&P 500 | 5,525.21 | 40.44 | 0.74% |
| S&P/ASX 200 | 8,007.70 | 39.50 | 0.50% |
| SSE Composite Index | 3,295.45 | 0.39 | 0.01% |